Estrella Immunopharma, Inc.
ESLAHealthcare|Biotechnology|US
$0.38
-0.03 (-8.49%)
DCF Value
$0.02
Cash / Share
$0.00
About
Estrella Immunopharma, Inc. is an early-stage biopharmaceutical enterprise focused on creating T-cell therapies for various blood cancers and solid tumors, with its primary activities centered in the United States. The company's lead investigational drugs include EB103, which is in preclinical development for diffuse large B-cell lymphoma, and EB104, intended for the treatment of both diffuse large B-cell lymphoma and acute lymphocytic leukemia. Estrella also maintains a collaborative agreement with Imugene Limited, working together to develop solid tumor therapies that integrate Imugene's CF33-CD19t product candidate with Estrella's EB103. The company is based in Emeryville, California.
Stock Price
-86.4%(1Y)
1M
-10.1%
3M
-48.1%
6M
-70.2%
YTD
-75.9%
1Y
-85.8%
3Y
-72.0%
5Y
-96.2%
Pipeline Summary
1 total trials1
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
Recruiting: 1
Active Trials (1)
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
NCT06343311B-Cell Non-Hodgkin's Lymphoma (NHL)
Phase 1Phase 2Recruiting
Enrollment: 27 participants
Key Facts
Market Cap$16.3M
Employees0 (-100% YoY)
CEOCynthia Pussinen
IPO DateSep 14, 2021
Beta0.89
52-Week Range$0.24 – $3
Avg Volume1,294,152
ExchangeNASDAQ
Websiteestrellabio.com
Ownership
Float39.6%
Shares Outstanding43.5M
Recent Insider Trades
Pussinen CynthiaAWARD
Nov 2, 20261,000,000 shares @ $0.43
Pussinen CynthiaOTHER
Oct 25, 20260 shares
Liu ChengOPTION EX.
Aug 25, 2026100,000 shares @ $0.81
Liu ChengOPTION EX.
Aug 25, 2026100,000 shares @ $0.81
Xu JiandongOPTION EX.
Aug 18, 2026100,000 shares @ $0.81
Peers
Recent News
Estrella Immunopharma Appoints Cynthia Pussinen as Chief Executive Officer and Chairperson of the Board of Directors
Oct 26, 2026 · businesswire.com
Estrella Immunopharma Treats First Patient with Two EB103 Infusions in STARLIGHT-1 Dose-Expansion Phase
Oct 15, 2026 · businesswire.com
Estrella Immunopharma Activates Intermountain Health LDS Hospital as Fifth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin's Lymphoma
Oct 14, 2026 · businesswire.com
Estrella Immunopharma (NASDAQ:ESLA) Trading Up 1.1% – Should You Buy?
Aug 21, 2026 · defenseworld.net
Data last updated: Nov 9, 2026, 04:09 AM